China's Akeso hits 9-month peak on progress of new drug development

Akeso

07/11/2023 03:43

** Shares of China's biological products developer Akeso Inc
 9926.HK  climb 5.2% to HK$49.40, the highest since Feb 3, in
their second session of gain
    ** Guangdong-based company says its AK104-302, a Phase III
clinical trial of cadonilimab in combination with chemotherapy
as first line treatment for gastric or gastroesophageal junction
adenocarcinoma, has reached primary endpoint of overall survival
at interim analysis
    ** Co says the independent data monitoring committee has
recommended to file a supplemental new drug application of
cadonilimab based on the interim analysis results of the trial
    ** Co says it is conducting multiple clinical trials of
cadonilimab combination therapies including cervical cancer,
gastric cancer, liver cancer, lung cancer, renal cancer,
esophageal squamous cell cancer
    ** Hong Kong's healthcare index  .HSCIH  falls 1.3% and Hang
Seng Index  .HSI  down 1.5%
    ** Stock up 11.9% YTD 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))